Efficacy and Safety of Adjuvant CDK4/6 Inhibitors in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: a Real-world Study
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
To evaluate the efficacy and safety of adjuvant CDK4/6 inhibitors in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Aged ≥18 and older
• Patients with pathologically confirmed breast cancer without distant metastasis or local recurrence
• HR+/HER2-
• ECOG 0-3
• Subjects meeting current guideline recommendations and planning to receive adjuvant CDK4/6 inhibitors
Locations
Other Locations
China
Renji Hospital, School of Medicine, Shanghai Jiaotong University
RECRUITING
Shanghai
Contact Information
Primary
Wenjin Yin, M.D.
yinwenjin@renji.com
86(21)68385569
Time Frame
Start Date: 2025-08-28
Estimated Completion Date: 2033-02
Participants
Target number of participants: 229
Treatments
Adjuvant CDK4/6 inhibitor
CDK4/6 inhibitors are drugs that block cell division in cancer cells. They are used with hormonal therapy for hormone receptor-positive breast cancer and may improve survival.
Related Therapeutic Areas
Sponsors
Leads: Wenjin Yin